The trial, a 108-patient randomized and controlled clinical trial, looked at venous leg ulcers that had been proven to be non-healing under standard treatment (compression therapy). In the study, half the patients had a common advanced wound care gel added to the standard treatment, and half had Comvita's Active Leptospermum (Manuka) Honey (now marketed under the brand name MEDIHONEY(TM)) added. After four weeks, 70% of the MEDIHONEY treated wounds versus only 16% of the hydrogel treated wounds had MRSA eradicated.
Published in this month's Journal of Wound Care, the research paper "Bacteriological Changes in Sloughy Venous Leg Ulcers Treated with Manuka Honey or Hydrogel: an RCT," was written by lead investigators Georgina T. Gethin and Seamus Cowman, both of the Royal College of Surgeons in Ireland. They concluded that for sloughy venous ulcers, "the efficacy of honey in eliminating MRSA in such wounds is a positive finding that may have implications for wound management and infection control."
Wound care is a major healthcare market with an estimated value of $10
billion in 2007, and is predicted to grow to $12.5 billion in 2012. The
global double-digit growth is being driven by several factors, including an
aging population, the rise in the global incidence of diabetes and chronic
vascular disorders, and a steady advancement in wound care technologies.
The advanced wound care segment encompasses a wide range of disparate
technologies that includes dressings and other devices. The three main
categories for dressings are: Traditional wound care such as gauze, moist
wound dressings designed to manage basic moisture issues, and active
dressings which incorporate technologies that provide additional benefits
such as antimicrobial activity. The active category is the fastest growing
|SOURCE Derma Sciences|
Copyright©2008 PR Newswire.
All rights reserved